{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:48:52Z","timestamp":1753890532041,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.00335","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T12:53:48Z","timestamp":1595595228000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment"],"prefix":"10.3389","volume":"10","author":[{"given":"Jiezuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renyong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.5551\/jat.RV17022","article-title":"Thrombus formation and propagation in the onset of cardiovascular events","volume":"25","author":"Asada","year":"2018","journal-title":"J. Atheroscler. Thromb"},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coph.2016.07.013","article-title":"Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics","volume":"30","author":"Chang","year":"2016","journal-title":"Curr. Opin. Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.compbiomed.2017.07.012","article-title":"Machine-learning-based classification of real-time tissue elastography for hepatic fibrosis in patients with chronic hepatitis B","volume":"89","author":"Chen","year":"2017","journal-title":"Comput. Biol. Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J. Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/iub.2044","article-title":"miR-146a-5p enhances hepatitis B virus replication through autophagy to promote aggravation of chronic hepatitis B","volume":"71","author":"Fu","year":"2019","journal-title":"IUBMB Life"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1097\/CCM.0b013e3181c9e31d","article-title":"Microvascular thrombosis and multiple organ dysfunction syndrome","volume":"38","author":"Gando","year":"2010","journal-title":"Crit. Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37015","DOI":"10.1038\/srep37015","article-title":"Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/s41598-019-42421-5","article-title":"Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment","volume":"9","author":"Guo","year":"2019","journal-title":"Sci. Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cellimm.2011.10.016","article-title":"Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection","volume":"272","author":"He","year":"2012","journal-title":"Cell. Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3851\/IMP3205","article-title":"Real-world evidence for nucleoside\/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results","volume":"23","author":"Jia","year":"2017","journal-title":"Antivir. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.3748\/wjg.v20.i19.5708","article-title":"Molecular diagnosis and treatment of drug-resistant hepatitis B virus","volume":"20","author":"Kim","year":"2014","journal-title":"World J. Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin. Transl. Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3389\/fimmu.2018.01561","article-title":"Hepatitis B virus adaptation to the CD8+ T cell response: consequences for host and pathogen","volume":"9","author":"Lumley","year":"2018","journal-title":"Front. Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00467-009-1262-2","article-title":"Biologically active ADAMTS13 is expressed in renal tubular epithelial cells","volume":"25","author":"Manea","year":"2010","journal-title":"Pediatr. Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nri2381","article-title":"Formation and function of the lytic NK-cell immunological synapse","volume":"8","author":"Orange","year":"2008","journal-title":"Nat. Rev. Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.25667","article-title":"Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B","volume":"56","author":"Otano","year":"2012","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5455\/medarh.2012.66.231-235","article-title":"Clinical significance of haemostatic tests in chronic liver disease","volume":"66","author":"Saray","year":"2012","journal-title":"Med. Arch"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1003208","DOI":"10.1371\/journal.ppat.1003208","article-title":"The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells","volume":"9","author":"Schurich","year":"2013","journal-title":"PLoS Pathog"},{"key":"B22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","article-title":"Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in Japan","volume":"54","author":"Suzuki","year":"2019","journal-title":"J. Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.imlet.2017.08.003","article-title":"Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: lessons learned from nucleos(t)ide analogues therapy","volume":"190","author":"Tavakolpour","year":"2017","journal-title":"Immunol. Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12185-009-0481-4","article-title":"Pivotal role of ADAMTS13 function in liver diseases","volume":"91","author":"Uemura","year":"2010","journal-title":"Int. J. Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1160\/TH08-01-0006","article-title":"Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis","volume":"99","author":"Uemura","year":"2008","journal-title":"Thromb. Haemost"},{"key":"B27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jvh.12997","article-title":"Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up","volume":"26","author":"van Campenhout","year":"2019","journal-title":"J. Viral Hepat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18139","DOI":"10.1074\/jbc.M116.737734","article-title":"Targeted reconstitution of cytokine activity upon antigen binding using split cytokine antibody fusion proteins","volume":"291","author":"Venetz","year":"2016","journal-title":"J. Biol. Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J. Viral Hepat"},{"key":"B30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/03007995.2016.1264932","article-title":"Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na\u00efve patients with chronic hepatitis B","volume":"33","author":"Wei","year":"2017","journal-title":"Curr. Med. Res. Opin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jhep.2014.10.002","article-title":"An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B?","volume":"62","author":"Wu","year":"2015","journal-title":"J. Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0169444","DOI":"10.1371\/journal.pone.0169444","article-title":"HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis","volume":"12","author":"Xing","year":"2017","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jvh.12626","article-title":"Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir","volume":"24","author":"Xu","year":"","journal-title":"J. Viral Hepat"},{"key":"B34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/jvh.12710","article-title":"Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144","volume":"24","author":"Xu","year":"","journal-title":"J. Viral Hepat"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T12:53:51Z","timestamp":1595595231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":34,"alternative-id":["10.3389\/fcimb.2020.00335"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.00335","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"article-number":"335"}}